Kristen Zakian1,
Jing Qi2, Yuman Fong3, Leonard Saltz4,
Michael D'Angelica3, Nancy Kemeny4, Mithat Gonen5,
Jinru Shia6, Amita Shukla-Dave1, Kinh Gian Do7,
William Jarnagin3, Lawrence Schwartz2, Jason A.
Koutcher1
1Medical
Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States;
2Columbia University College of Physicians and Surgeons, New York,
NY, United States; 3Surgery, Memorial Sloan-Kettering Cancer
Center, New York, NY, United States; 4Medicine, Memorial
Sloan-Kettering Cancer Center, New York, NY, United States; 5Epidemiology
and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY,
United States; 6Pathology, Memorial Sloan-Kettering Cancer Center,
New York, NY, United States; 7Radiology, Memorial Sloan-Kettering
Cancer Center, New York, NY, United States
To evaluate hepatic triglyceride changes during and after adjuvant chemotherapy in colorectal cancer patients, 1H MRS was performed prior to chemotherapy, after 6 months of treatment and at 1 year follow up. Nine FOLFOX-treated patients and 7 patients treated with hepatic arterial infusion of FUDR and systemic irinotecan (HAI-FUDR/IRI completed this 1 year study. FOLFOX patients who experienced an increase in fat to fat+water ratio (FFW) during treatment tended to return toward baseline after 6 months off-treatment unless they experienced a significant weight-gain. HAI-FUDR patients did not show a trend toward increasing hepatic lipids while on treatment.